Compare SABR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | ADCT |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.7M | 484.4M |
| IPO Year | 2014 | 2019 |
| Metric | SABR | ADCT |
|---|---|---|
| Price | $1.55 | $4.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.70 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 16.7M | 812.5K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 44.90 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,866,956,000.00 | $70,837,000.00 |
| Revenue This Year | $7.40 | $14.96 |
| Revenue Next Year | $3.26 | $1.06 |
| P/E Ratio | $1.20 | ★ N/A |
| Revenue Growth | ★ 7.46 | 1.84 |
| 52 Week Low | $0.81 | $1.05 |
| 52 Week High | $3.86 | $4.80 |
| Indicator | SABR | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 51.41 |
| Support Level | $1.20 | $3.25 |
| Resistance Level | $1.70 | $4.71 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 64.29 | 29.76 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).